Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Oil Reservoir Analy

21 Jul 2008 07:00

RNS Number : 4429Z
ViaLogy PLC
21 July 2008
 



VIALOGY SHOWS EARLY SUCCESS IN OIL RESERVOIR ANALYSIS

London, July 21, 2008. ViaLogy PLC (LSE: VIY), announces completion of the initial phase of its pilot project with Atascosa Exploration LLC ("Atascosa") to apply its QuantumRD™ technology for geoseismic applications to determine the location and characteristics of underground oil deposits. 

With reference to a prospective Texas drilling site, the QuantumRD analysis confirmed the location of an oil trap, and mapped its size, shape, and predicted porosity. Atascosa estimates that this finding will save them over $500,000 by relocating the drill site to an optimal location some 700 feet from the site originally planned. In addition, ViaLogy's analysis discovered a second, deeper gas and oil trap of at least equal size. Work to drill both wells will begin in the coming weeks.

"We are very encouraged by ViaLogy's report, although final confirmation must await the results of drilling," said Atascosa CEO, John D. Mullins. "Our production engineering and geophysicist team is particularly impressed by the analysis tools Vialogy brings to bear in its novel approach to accurately characterizing reservoir prospects using existing datasets. We will look to grow our strategic collaboration with ViaLogy in analytical facets of reservoir modeling, water injection planning and enhanced recovery."

"The discovery of the new reservoir is remarkable, and could prove a significant find."

Atascosa confirmed that as payment for its QuantumRD work Vialogy is to receive a no-cost 5% working interest (WI), subject to existing agreements, royalty interest (RI), and overriding royalty interests (ORRI) in the wells drilled for each sand after payout of lease costs, geology, engineering, drilling, and other operational expenses. At each well payout, Atascosa will execute and deliver assignments to Vialogy sufficient to vest Vialogy with ownership of its 5% WI in the initial well in each sand and its right to participate in additional wells on the same basis as the other owners and as covered by the Operating Agreement.

The company estimates that this could produce approximately $8 million for Vialogy over the life of the wells. ViaLogy President and CEO Robert W. Dean stated; "We are very pleased to partner with Atascosa to commercialize our technology in the energy market. Atascosa's domain expertise will help us reach a broader problem and customer set. Geoseismology is an excellent vertical for us, as we will be able to realize a higher margin and performance premium for our disruptive technology. We are working with the Atascosa team to identify additional growth areas that we can address in the near-term."

For Further Information please contact:

ViaLogy Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656)

Nominated Advisor Seymour Pierce Mark Percy +44 (0) 20-7107-8000 

PR Consultants - Redleaf Communications  Emma Kane / Samantha Robbins +44 (0) 20-7822-0200 

About ViaLogy: Network Centric Signal Processing.

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFWFIASASEFW
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.